Copyright: ©Author(s) 2026.
World J Gastroenterol. Jun 14, 2026; 32(22): 118323
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118323
Published online Jun 14, 2026. doi: 10.3748/wjg.v32.i22.118323
Figure 6 Survival outcomes according to preoperative and postoperative circulating tumor DNA status after resection.
A and B: Recurrence-free survival (A) and overall survival (B) curves comparing patients with detectable vs undetectable preoperative circulating tumor DNA levels among those who underwent resection after neoadjuvant chemotherapy (n = 23); C and D: Recurrence-free survival (C) and overall survival (D) curves comparing patients with detectable vs undetectable postoperative circulating tumor DNA levels in the combined cohort of upfront resection and post-chemotherapy resection groups (n = 32). ctDNA: Circulating tumor DNA.
- Citation: Jung K, Lee J, Jang D, Ahn J, Kim B, Yang S, Kim JH, Youn Y, Lee JC, Kim J, Hwang JH. Serial circulating tumor DNA as a biomarker for monitoring and prognostication in patients with pancreatic cancer. World J Gastroenterol 2026; 32(22): 118323
- URL: https://www.wjgnet.com/1007-9327/full/v32/i22/118323.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i22.118323